Prospective studies of diagnostic test accuracy have important advantages over retrospective designs. Yet, when the disease being detected by the diagnostic test(s) has a low prevalence rate, a prospective design can require an enormous sample of patients. We consider two strategies to reduce the costs of prospective studies of binary diagnostic tests: stratification and two-phase sampling. Utilizing neither, one, or both of these strategies provides us with four study design options: (1) the conventional design involving a simple random sample (SRS) of patients from the clinical population; (2) a stratified design where patients from higher-prevalence subpopulations are more heavily sampled; (3) a simple two-phase design using a SRS in the first phase and selection for the second phase based on the test results from the first; and (4) a two-phase design with stratification in the first phase. We describe estimators for sensitivity and specificity and their variances for each design, along with sample size estimation. We offer some recommendations for choosing among the various designs. We illustrate the study designs with two examples.
INTRODUCTION
In diagnostic medicine both retrospective and prospective designs are used to assess and compare the accuracy of diagnostic tests. In a retrospective design patients are usually recruited based on whether or not they have the disease of interest; specified numbers of patients with and without the disease are entered into the study. In contrast, the true disease status of a patient is unknown at the time of recruitment for a prospective study; here, patients are selected based on their symptoms or lack thereof. A prospective design has important advantages over a retrospective design, including a patient sample that is better defined in terms of the patients' clinical characteristics, and standardized methods for performing and interpreting the test(s) and gold standard procedure. In some circumstances a prospective design is the only possible approach due to the nature of the test or disease under investigation. For example, when tests are to be used as screening tools, it is critical that their accuracy be measured on the relevant clinical We want to estimate the accuracy of the new test in patients with risk factors for cardiovascular disease but no known MIs. The prevalence of silent MIs in this population is only about 3%.
In the second example we want to compare the diagnostic accuracy of direct digital mammography to standard film-screen mammography for a breast cancer screening population. Film screen is the standard modality for screening for breast cancer. Digital mammography is a new technique which offers easy storage and transfer of images and various lesion enhancement tools. Both digital and film mammography deliver a small dose of ionizing radiation which is expected to cause several cancer deaths per year (i.e. 1 death per 7246 women (Committee on the Biological Effects of Ionizing Radiation, 1990) ). Furthermore, since digital mammography is not approved for screening yet, all screening patients must undergo film mammography. Our goal is to find a study design that minimizes the number of patients undergoing both tests.
In Section 2 we describe estimators for sensitivity and specificity for each study design, along with estimators for their variance. In Section 3 we describe sample size estimation. We focus on sample size estimation for sensitivity because we consider situations where the prevalence rate is low; thus, we presume that the sample size for patients without disease will be adequate for narrow confidence intervals for specificity. We offer some recommendations for choosing among the designs in Section 4. We apply these recommendations to the two examples (Section 5). A discussion follows. Table 2 summarizes the data from a conventional design for one diagnostic test. A simple random sample of N S RS patients is taken from the population. All N S RS patients are tested and verified. m 1 patients are determined to have disease and m 0 patients do not. The test is positive in s 1 patients with disease and negative in r 0 patients without disease. The estimator of sensitivity is simply Se = s 1 /m 1 . Similarly, the estimator of specificity is Sp = r 0 /m 0 . The estimator of the variance of Se is Se(1 − Se)/m 1 , and the estimator of the variance of Sp is Sp(1 − Sp)/m 0 . An asymptotic (1 − α)% confidence interval (CI) for sensitivity is
ESTIMATION OF SENSITIVITY AND SPECIFICITY

Conventional design
where z 1−α/2 is the value from the cumulative standard normal distribution. See Agresti and Coull (1998) for an alternative CI based on the score test (Wilson, 1927) which provides better coverage for small samples and sensitivity close to 1.0. Now suppose there are two diagnostic tests being compared, where all patients undergo both tests (i.e. paired design). Let Se ( j) denote the sensitivity of test j and Sp ( j) denote its specificity. The estimator for the sensitivity of test j is Se
1 is the number of patients with disease who test positive on test j. Similarly, the estimator of specificity is
An estimator of the covariance of Se (1) and 
1k is the test result (i.e. 0 or 1) on test j for the kth patient with disease. The estimator of the covariance of Sp (1) and Sp (2) is similar. An estimator for the variance of the difference in sensitivities of the two tests is
To test the hypothesis that the two tests' sensitivities are equal, versus the alternative hypothesis that the tests' sensitivities are different, we compare the test statistic in (4) to a standard normal distribution.
where Var 0 ( Se (1) − Se (2) ) is the estimate of the variance under the null hypothesis. It is computed by taking the average of Se (1) and Se (2) , call it Se (0) , and substituting Se (0) for Se (1) and Se (2) .
Stratification design
During the design phase of the study, suppose we are aware of a subpopulation(s) with a higher prevalence of disease. For example, in the silent MI study we know that patients with coronary artery disease (CAD) have a higher prevalence of silent MIs than patients without CAD. Similarly, we know that women with a personal history of cancer have a higher prevalence of breast cancer than women without a personal history. In the stratified design we apply this knowledge to sample efficiently from these subpopulations. Specifically, we sample N (i) patients from subpopulation i, such that
where I is the number of subpopulations.
To estimate the test's sensitivity and specificity in the population, we first estimate the sensitivity and specificity in each stratum. Then, an estimate of the test's accuracy for the population is a weighted average of these I estimates of accuracy (Kish, 1965; Sukhatme and Beam, 1994) ,
where
is the estimated sensitivity from stratum i, and W 1(i) is the population proportion of all diseased patients belonging to stratum i. We assume that the weights are known. An estimate of the test's specificity is 
is the estimated specificity from stratum i and W 0(i) is the known population proportion of all nondiseased patients belonging to stratum i. The estimator of the variance of Se is
where Var(
The estimator is similar for Var( Sp). We construct a (1 − α)% CI for sensitivity using equation (1). When there are two tests applied to the same sample of patients, we denote the sensitivity and specificity of test j within the ith stratum as Se
To estimate Se ( j) and Sp ( j) for the two tests we first estimate the sensitivity and specificity of the two tests in each of the I strata, then use the weighted average estimators in equations (5) and (6). The estimator of the variance of Se ( j) is given in equation (7). An estimator of the covariance of Se (1) and Se (2) is
where Cov( Se
(i) ) is given in equation (2). The test statistic in (4) can be used to test the null hypothesis that the tests' sensitivities are the same. Table 3 summarizes the data from a simple two-phase design for a single diagnostic test. A random sample of N S2P patients undergo the diagnostic test. We consider the case where we verify all n 1 patients who test positive and a random sample of size f × n 0 of the n 0 patients who test negative. Other sampling schemes for the second phase are possible as well: for example, see Deming (1977) and Irwig et al. (1994) . However, for many studies of diagnostic tests, all patients with positive test results in the first phase will necessarily undergo further testing for clinical reasons, whereas the patients with negative test results will not undergo further testing. Thus, the proposed sampling scheme for the second phase follows closely the clinical course of these patients which we take advantage of here.
Simple two-phase design
There are u patients who tested negative on the test and who were not verified (u = n 0 × (1 − f )). V S2P denotes the number of patients who undergo disease status verification. If the conditions are right (See section 4 for a discussion of these conditions), V S2P will be substantially smaller than N S2P .
The data in Table 3 resemble a dataset with verification bias. Since the study design dictates who will undergo verification and who will not, the missing at random assumption (i.e. the assumption that 
verification is based only on the test results and not on the underlying disease status) is met. Estimators of sensitivity and specificity are
We use the following consistent estimators of variance:
. Begg and Greenes (1983) proposed a logit-transformed version of these variance estimators. A (1 − α)% CI for sensitivity can be constructed from equation (1) using the estimators in (9) and (10). See Waller et al. (1994) for other methods for CI construction in two-phase sampling studies. Suppose we want to compare two diagnostic tests. One approach is to perform both tests in phase one, then verify a subsample of the patients in phase two. Zhou (1998) describes the MLEs for this design. For the mammography study, however, we need a different design because we need to minimize the number of patients who undergo the second test. Thus, in the first phase we take a random sample of patients from the population and apply the first test (e.g. film mammography). If the first test is positive, then the patients undergo the second test (e.g. digital mammography) and the gold standard procedure (e.g. biopsy or follow-up imaging at one year). If the first test is negative, then a random sample of size f × n 0 of the n 0 patients who tested negative undergo the second test and the gold standard procedure. Table 4 summarizes the data. Let T (1) denote the result of the first test and T (2) denote the result of the second test. s cd denotes the number of diseased patients who underwent the gold standard procedure and whose test result was c on the first test (c = 1 or 0) and d on the second test (d = 1 or 0). There are u patients who tested negative on the first test and who did not undergo the second test or the gold standard procedure.
Let
The log-likelihood function is just the sum of the logs of these terms, weighed by the cell counts from 
Let p = 1 c,d=0 ψ 1cd ψ 2cd . The sensitivity of the first and second tests are
Similarly, the specificities of the two tests are
The MLEs are obtained by replacing the unknown parameters in equations (13) and (14) by their corresponding MLEs in equation (12). There are a number of approaches to estimating the standard errors and covariances ofŜe (1) and Se (2) and alsoŜp (1) andŜp (2) . We derived the asymptotic theory-based standard errors and covariances; the estimators can be found at http://www.bio.ri.ccf.org/Research/ProspectiveDesign/asympvar.pdf. As an alternative to the asymptotic estimators, we performed a simulation study to assess how well a simple bootstrap estimate of the standard error of the difference in sensitivities of two tests performs. See also Pickles et al. (1995) for several other approaches to estimating the variance from a simple two-phase design, including Bayesian estimation (see Erkanli et al. (1997) ) and applications of a generalized linear mixed model (see Gornbein et al. (1992) ).
Our bootstrap method involves taking a random sample of size N S2P from the original dataset. For the bth bootstrap sample, we estimate f , the proportion of observations in the bootstrap sample who underwent both tests among all observations who tested negative on the first test. (Note that the value of f is not fixed in the bootstrap samples, whereas it is fixed by design in the original data.) We then estimate Se (1) and Se (2) using equation (13), denoting them Se (1)b and Se (2)b for the bth sample. Let
we compute the bootstrap estimate of variance for the difference in the estimated sensitivities as
The test of the null hypothesis is ( Se
Var boot , which we compare to a standard normal distribution.
The simulation study (the detailed results of which can be found at http://www.bio.ri.ccf.org/Research/ProspectiveDesign/asympvar.pdf) showed that the power and type I error rate of the asymptotic and bootstrap methods are very similar. The asymptotic estimator of variance cannot be computed, however, when s 00 is zero; the rate of these occurrences increases as N S2P decreases and/or as f decreases. Also, the type I error rates of both the asymptotic and bootstrap methods are higher than the nominal level of 5% unless N S2P is very large. In particular, the type I error rate is sensitive to the value of s 00 . We found that as long as the expected value of s 00 is 4 or greater, the type I error rate of the bootstrap method was near the nominal level; in these circumstances the asymptotic estimator can often be calculated, but not always.
Two-phase design with stratification in first phase
Suppose we have divided the population into I strata based on the conjectured prevalence rates of disease. To estimate the sensitivity of a single test, we sample N (i) from each stratum, where
In each stratum we verify the disease status of all patients who test positive and a random sample of size f × n 0(i) of the n 0(i) patients who test negative. (Note that for simplicity in calculations and in performing the study, we keep f constant in each stratum; however, this is not necessary.) Let V (i) denote the number of patients verified from each stratum. We use the estimators of sensitivity and specificity in equation (9) for each stratum. Then, the accuracy for the population can be estimated using the estimators in equations (5) and (6). Note that these estimators of accuracy are equivalent to Begg and Greenes' (1983) estimators for the case of stratified data.
The estimator of the variance of Se is given in equation (7), where Var( Se (i) ) is given in equation (10). Begg and Greenes (1983) proposed a logit-transformed version of this variance estimator (see their equation (6.3)). A (1 − α)% CI can be constructed for sensitivity using equation (1).
Suppose we are comparing two tests. We construct estimators of sensitivity and specificity using equations (13) and (14) for each stratum. Then we take a weighted average over the strata using equations (5) and (6). The estimate of the variance of the difference in sensitivities (or specificities) is a weighted average of the I strata variances of the differences. The variance estimate from each stratum can be obtained in several ways, including the asymptotic theory-based and bootstrap methods proposed in Section 2.3.
CALCULATING SAMPLE SIZE
For single-test studies we base our sample size estimate on the desired width of the (1 − α)% CI for sensitivity. When comparing two tests, we base our sample size estimate on the desired power to detect the conjectured difference in the tests' sensitivities. We focus on sensitivity because we are considering situations where the prevalence of disease is low. Usually the sample size will be more than adequate for assessing specificity; however, the expected width of the CI for specificity and the power for comparing tests' specificities should also be examined.
Conventional design
For single-test studies we use equation (15) to determine the number of patients needed for the study:
where L is the desired width of one-half of the CI, p 0 is the conjectured prevalence of disease in the sample, and Se 0 is the conjectured sensitivity of the test. When testing the null hypothesis that two tests' sensitivities are the same versus the alternative hypothesis that the tests' sensitivities are different (two-tailed), we use equation (16) 
is the conjectured sensitivity of test j under the alternative hypothesis, δ = Se 0
(1) − Se 0 (2) , V 0 = 2 × Se 0 (1 − Se 0 ), Se 0 is the sensitivity of the two tests under the null hypothesis, and β is the type II error rate. For simplicity, we compute a conservative estimate of the required sample size, which assumes that the samples are independent (Connor, 1987) .
Stratification design
For this design, the desired width of one-half of the CI is given by
where Se 0(i) is the conjectured sensitivity for stratum i, p 0(i) is the conjectured prevalence of disease in stratum i, and N (i) is the total number of patients to be sampled from stratum i. There are I unknown sample sizes. For convenience, we wrote a simple Fortran program that searches through a large range for the sample sizes (i.e. a large range for the N (i) ). For each combination of sample sizes, the program calculates L using equation (17). The program identifies the designs with the smallest total sample size. We then identify the study design that has the lowest required sample size for the subpopulation with the lowest relative frequency. When comparing two tests' sensitivities, the conjectured difference in sensitivity, i.e. δ, can be written as
)
and Se 0(i) ( j) is the conjectured sensitivity of test j for stratum i under the alternative hypothesis. Var 0 is computed in the same way except that the conjectured sensitivity under the null hypothesis is substituted for Se 0(i)
(1) and Se 0(i) (2) . We wrote a Fortran program to find the smallest sample size.
Simple two-phase design
In planning a single-test study we want to determine N S2P as a function of f . The required sample size, N S2P , is given by
). An estimate of the number of patients who will undergo disease status verification iŝ
Then, an estimate of the percentage savings over a conventionally designed prospective study is
where C = C V /C T , and C V and C T are the costs of performing the gold standard procedure and the diagnostic test, respectively. When comparing two tests using the simple two-phase design, it is difficult to compute sample size because, for both the asymptotic and bootstrap methods, we cannot write N S2P in terms of just the conjectured sensitivities, specificities, and prevalence rates. Thus, our approach is to simulate data based on the conjectured sensitivities, specificities, prevalence rates, and for initial values of sample size and f . For each simulated dataset we use both the asymptotic and bootstrap methods described previously to test the hypothesis that the sensitivities of the two tests are equal. We estimate power as the proportion of simulated datasets in which the null hypothesis is rejected at a significance level of 5%. Based on the estimated power, we revise the sample size and f until we find a design with the specified power.
Two-phase design with stratification in first phase
For single-test studies, the desired width of one-half of the CI is given by
We wrote a Fortran program that searches through a large range of sample sizes and values for f to find the smallest sample size that yields the desired value of L. Our approach to sample size determination for studies comparing two tests is the same as for the simple two-phase design, i.e. an iterative process of simulating data based on the conjectured accuracies, values of sample sizes, and f and then estimating power from the simulated data.
CHOOSING THE BEST STUDY DESIGN
There are multiple factors that affect the number of patients required for the various study designs in Table 1 . We compared the designs for a range of study parameters to provide some guidance in choosing among them.
Stratification design
A stratified design can only be used if information is available before the study begins that allows us to stratify the clinical population based on the prevalence of disease. When stratification is possible, then the primary factors influencing the savings afforded by this design are (1) the difference in prevalence rates between the strata, and (2) the relative frequency of the strata in the population. As the difference in prevalence rate increases, the savings over a conventional design increases. Also, when the high-risk subpopulation is a small subset of the overall population, the savings over a conventional design is greater as the relative frequency of this high-risk subpopulation in the overall population increases. 
Simple two-phase design
For single-test studies, the simple two-phase design is recommended when (i) the test's sensitivity is only moderate at best (< 70%), (ii) the specificity is high (> 80%), and (iii) the cost of verifying patients is much greater than the cost of testing (C > 5). Even under these ideal situations, the savings over a conventional design are only modest, usually < 15%. Figure 1 illustrates the effect of the test's sensitivity and specificity on the percent savings afforded by this design over a conventional design. Here the cost to verify a patient is set at 10 times that of testing the patient. When the test's sensitivity is low, say 60%, and the specificity is high, say 90%, we save 5% in costs by verifying the disease status of 59% of test-negative patients (i.e. f = 0.59). If the test's sensitivity is less, say 50%, the savings increases to 11%. However, if the test's sensitivity is higher or the specificity is lower, the savings dwindles. This makes intuitive sense: a two-phase design is cost-effective only when there are many FNs to sample in the second phase and few FPs to verify. The simple two-phase design offers more advantages when comparing two tests. For example, in the mammography study (see Section 5.2) where the sensitivity of film is set at 0.78 and specificity at 0.90, a simple two-phase design can provide a 28% savings over a conventional design and a 12% savings over a stratified design. When the first test's sensitivity is higher than 0.78, there is still substantial savings over both the conventional and stratified designs, but the expected value of s 00 may become small. Also, as the specificity of film decreases, the savings dwindles because many false positives will undergo the second test.
There are other issues to consider with the two-phase design. The first is the duration of the study. In the mammography example, the best design required 25 000 patients in the first phase, of which only 8250 were selected for the second phase. In contrast, the conventional design required 11 506 patients; thus, the study duration might be twice as long for the simple two-phase design. Irwig et al. (1994) rate (for studies comparing two tests). When the sample sizes, particularly s 00 , are small, the coverage and type I error rate are less than the nominal level. We recommend, in addition to the sample size calculation, that one also calculate the expected value of s 00 . A reasonable value for s 00 is 4 or more. A third issue to consider is the necessary extra administrative attention required in selecting patients for the second phase.
As Deming (1977) pointed out for single-test studies, these added costs should be incorporated into C T .
Two-phase design with stratification in first phase
The situations in which a stratified design are effective are quite different from the set of circumstances when a two-phase design is effective. These two strategies, thus, can be used in complementary roles. Figure 2 illustrates the single-test scenario where the difference in the two strata prevalence rates is 5% and the high-prevalence stratum is 25% of the population. The overall sensitivity is low (0.67) and the specificity is high (0.95). A stratified design (STR) offers a 19% savings over the conventional design. A simple two-phase design (S2P) offers a savings of 0% to 11%, as the cost of verifying relative to testing (C) increases from 1 to 50. The two-phase design with stratification in the first phase (2PST) offers a savings exceeding that of any other design as long as C is greater than or equal to 5. When comparing two tests, the stratified two-phase design may be useful as long as the prevalence of disease is not too low. We encourage users to calculate the expected value of s 00 for each stratum before choosing this study design.
EXAMPLES
Silent MIs study
The goal of the study is to estimate the accuracy of a new test for detecting silent MIs. We expect that the prevalence of silent MIs in asymptomatic patients without CAD is about 1%. However, the prevalence of silent MIs among patients with CAD is expected to be higher, maybe 8-10% (for sample size estimation, we use the lower value). CAD patients make up approximately 25% of the at-risk population.
The new test's specificity is expected to be high, 95%. The sensitivity is lower: 75-80%. We don't know if the sensitivity of the new test differs for CAD and non-CAD patients. If we knew the accuracy of the test was the same for these two strata, we could just sample CAD patients. However, to be on the conservative side, we assume that the sensitivities of the two strata are different, and thus we will sample from both subpopulations. We want to estimate the new test's sensitivity to within ±0.10 (i.e. L = 0.10).
The sample size for a conventional design is 2347-2522, depending on the test's sensitivity in the two subpopulations. A stratified design offers a substantial savings: by recruiting nearly as many patients from the CAD subpopulation as from the non-CAD subpopulation (i.e. about 905 and 975, respectively), we save 20-26%.
In the two-phase designs the optimum fraction of test-negative patients who should undergo MRI is about f = 0.67. The simple two-phase design does not offer much savings over a conventional design (2-3%); it requires 3250-3464 total patients in the first phase, of which an expected 2253-2400 would undergo disease verification in the second phase. A two-phase design with stratification in the first phase offers a large savings over a conventional design (22-27%) and a small additional savings over a stratified design (1-2%). It requires 2575-2590 total patients in the first phase, of which an expected 1794-1805 would undergo disease verification in the second phase. This more complex design may not be worthwhile if the savings is only 1-2% over a stratified design. In addition, for the non-CAD subpopulation, we'd expect s 0 to be only 3; thus, we may encounter difficulties with the coverage of CIs.
Film versus digital mammography study
For illustration, we consider two subpopulations: those with a personal history of breast or cervical cancer and those without a personal history. The prevalence of breast cancer in a single screening of women without a personal history is 0.5%, but is much higher in women with a personal history, approximately 5% (value used for illustration). Patients with a personal history of cancer make up about 10% of the screening population. The gold standard is biopsy for patients with suspicious lesions on either diagnostic test and follow-up with imaging at 1 year for patients without a suspicious lesion.
Suppose we want to detect a difference in sensitivity between film and digital of 0.15. We assume that for patients with and without a personal history, film mammography has a sensitivity of 0.80 and 0.75, respectively. We assume the specificity is 0.90 for both subpopulations and both tests.
For a study with 5% type one error rate and 80% power, the conventional design requires a total sample size of 11 506 patients (based on Connor (1987) ). All 11 506 patients undergo both film-screen and digital mammography. The stratified design, on the other hand, requires a total sample size of 9370 (19% savings), with 2180 coming from the subpopulation with a personal history and 7190 from the subpopulation without a personal history. All 9370 patients undergo both film-screen and digital mammography.
The best simple two-phase design is as follows: 25 000 patients undergo film-screen mammography. All patients who test positive on film-screen mammography and 25% of patients who test negative (i.e. f = 0.25) undergo digital mammography and the gold standard procedure. An estimated 8250 patients will undergo both film-screen and digital mammography. This design offers a savings, in terms of the number of patients who must undergo digital mammography, of 28% over a conventional design and 12% over a stratified design.
For a two-stage design using stratification in the first phase, the expected value of s 00 is < 4 for the subpopulation of patients without a personal history of cancer. Thus, this design is not recommended for this example.
DISCUSSION
Diagnostic test accuracy studies are difficult to design because of the many sources of bias that are common in these studies (Begg, 1987; Reid et al., 1995) . Prospective studies are especially difficult when the prevalence of disease in the population is low. We presented and illustrated two strategies to help reduce the sample size for prospective studies with low prevalence rates. There are other approaches that we have not discussed, some invalid and others valid.
One common, but naive, approach is to verify the true disease status only for the patients who test positive, then estimate the test's accuracy, or difference in two tests' accuracies, based only on the patients with verified disease status. Clinicians often refer to the patients in this approach as the 'enriched' population because the prevalence of disease is augmented. They expect that since the 'enriched population' includes patients both with and without the disease, then test accuracy can be appropriately estimated. However, this is untrue because the 'enriched' population is also a highly selected one, and estimates of test accuracy computed from this population will be biased (Begg, 1987) .
One valid approach using such an 'enriched' population was proposed by Schatzkin et al. (1987) for the situation where the accuracy of two tests are being compared. They perform both tests on all patients, then estimate the ratio of the two tests' sensitivities (or specificities) based only on the patients who tested positive on one or both tests. The sample size required in this approach is equivalent to the conventional design, but there is a substantial monetary savings over the conventional design because only patients who test positive need to be verified. Cheng and Macaluso (1997) , Pepe and Alonzo (2001) , and Baker and Pinsky (2001) have proposed extensions for the estimation of relative accuracy for this design. This design, however, would not be effective in situations such as our mammography study. In that study the goal was to reduce the number of patients who must undergo both tests in order to reduce the radiation. The approach by Schatzkin et al. would eliminate the need to follow-up patients whose film and digital mammography exams are both negative; however, there is no savings in terms of the number of patients who must undergo both tests.
Still another option is a prospective, unpaired design. Subjects are randomized to one of the tests, the gold standard procedure is performed on all study patients, and the accuracies of the tests are compared. An unpaired design usually requires a larger sample than a paired design, but sometimes an unpaired design is required when one or both tests is invasive, risky, or interferes with the other test.
In this paper we emphasized estimation of sensitivity and specificity for the various designs. For the stratified designs we assumed that the weights for the strata are known. If the weights are unknown, then variance estimators such as those proposed by Begg and Greenes (1983) (see their equation (6.2)) should be used. Regardless of whether the weights are known prior to the study or must be estimated from the data, it's important to report the weights, along with the stratum-specific estimates of accuracy, because these weights will undoubtably vary between clinical populations. We also note that positive and negative predictive values can be easily estimated for the designs presented in this paper. For example, in the simple two-phase design, estimators of PPV and NPV for a single-test study are s 1 /n 1 and r 0 /(n 0 − u), respectively; when comparing two tests, the estimators for the second test are (s 11 + s 01 / f )/(s 11 + r 11 + (s 01 + r 01 )/ f ) and (r 10 + r 00 / f )/(s 10 + r 10 + (s 00 + r 00 )/ f ), respectively.
